takeda neurocrine - Search News

Takeda, Neurocrine and Major depressive disorder

Takeda regains home rights to phase 3-stage depression drug from Neurocrine

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences.

YAHOO!Finance · 2d

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE:TAK) to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement,

MarketWatch · 3d

Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

TipRanks on MSN · 3d

Neurocrine Amends License Agreement with Takeda

An announcement from Neurocrine ( ($NBIX) ) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive

Business Insider · 3d

Neurocrine announces amendment to collaboration with Takeda

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the

2don MSN

Stifel maintains Neurocrine Bio stock target, positive on Takeda deal

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...

Neurocrine’s Strategic Partnership with Takeda: A Catalyst for Growth and Financial Upside

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...

The Pharma Letter2d

Neurocrine revamps osavampator deal with Takeda

USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...

BioSpace2d

Neurocine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

Pharmabiz1d

Neurocrine Biosciences and Takeda amend strategic collaboration to develop and commercialize osavampator

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results